ArticleThe Lancet regional health. Europe2026
Incidence and Clinical, Virological, and Resistance Characteristics of HIV Infections Among pre-Exposure Prophylaxis Users in Spain (SCOPE Study): A Multicentre Prospective and Retrospective Cohort Study.
Article in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Implemented in Spain in 2019, pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention strategy that reached an estimated 28,800 users by 2024. We aimed to address HIV incidence and characteristics in PrEP users. Methods: Ambispective observational cohort study conducted across 12 centers in Spain. Data from adults diagnosed with HIV who had used oral PrEP within six months prior to seroconversion were collected from August 2024 to March 2025. Main outcomes were HIV incidence among PrEP users, and clinical, virological, and drug resistance characteristics at diagnosis for all cases, as well as 12-month follow-up data for retrospective cases. Findings: Until March 2025, 53 seroconversions occurred among 19,884 PrEP users, yielding an incidence of 0.06 cases per 100 person-years (95% CI: 0.01-0.15). Most individuals were cisgender men who have sex with men (91%), median age of 32 years [IQR:27-37], and from Latin America (31/52; 60%) or Spain (17/52; 33%). Chemsex was reported by 24 (45%), and 49% had a concomitant sexually-transmitted infection. Daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) was the most frequent regimen (36/50; 72%). PrEP interruptions occurred in 71% (32/45) and 42% (15/36) had suboptimal adherence. Time on PrEP at diagnosis was 8 months [IQR:3-19] and time from last negative to first positive HIV test 3.6 months [IQR:2.7-9.3]. Baseline median viral load (VL) was 14,917 copies/mL [IQR:825-221,000]. Resistance testing was successful in 90% of individuals (44/49), with nucleos(t)ide reverse transcriptase inhibitor-related substitutions detected in 41% (18/44), mainly M184V/I. Thirty-five retrospective cases completed 1-year follow-up, with VL suppression of 87% (20/23) at 12 months. Interpretation: PrEP interruptions and/or poor adherence were very prevalent. Most cases were migrants and chemsex use was frequent. Resistance substitutions were frequently found. Despite overall low HIV incidence, some subgroups of PrEP users require additional interventions to prevent HIV. Funding: ISCIII (PI23/00355).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.